A recent large scale human clinical study, called as PIVENS, with 247 adults found that pioglitazone, a PPAR-γ agonist, significantly reduce steatosis (Sanyal et al., 2010) contrary to what we would expect if PPAR- γ agonism is a MIE for steatosis. This evidence concerns the gene PPARG and steatosis.